NVS - Incyte/Novartis' Jakafi study in COVID-19 fails to meet endpoints

Incyte's (INCY) Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi) plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. RUXCOVID study was sponsored by Incyte in U.S. and Novartis (NVS) outside of U.S.Initial data show that there was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit ((ICU)) care by Day 29, compared to SoC treatment alone (12.0% vs. 11.8% [OR: 0.91 [95% CI: 0.48-1.73], P=0.769, respectively). In addition, there was no clinically relevant benefit observed among secondary and exploratory endpoints, including mortality rate by Day 29 and time to recovery.Ruxolitinib was generally well tolerated and no significant safety concerns were identified. A comprehensive analysis including safety data is ongoing. The data will

For further details see:

Incyte/Novartis' Jakafi study in COVID-19 fails to meet endpoints